Skip to main
JSPR

Jasper Therapeutics (JSPR) Stock Forecast & Price Target

Jasper Therapeutics (JSPR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Jasper Therapeutics Inc is advancing its innovative hematopoietic stem cell therapies, demonstrating promising efficacy with an impressive 89% complete response (CR) rate across two dosing cohorts, highlighting the potential effectiveness of its treatment options. The company's focus on safer and more effective conditioning agents positions it favorably within the biotechnology sector, particularly as it seeks to expand the use of stem cell transplantation and gene therapy. Additionally, the differentiation of its lead product, briquilimab, through its shorter half-life may offer competitive advantages in safety and patient outcomes compared to existing therapies.

Bears say

Jasper Therapeutics has experienced a notable decline in stock value due to complications surrounding a faulty drug lot for briquilimab, which has also led to a pause in the ETESIAN trial for asthma. Additionally, the company raised $30 million through common stock and pre-funded warrants, which may indicate financial distress and a need for liquidity. The updated diluted share count has further pressured the stock price, leading to a significant downward revision of the company's price target from $20 to $7.

Jasper Therapeutics (JSPR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Jasper Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Jasper Therapeutics (JSPR) Forecast

Analysts have given Jasper Therapeutics (JSPR) a Buy based on their latest research and market trends.

According to 8 analysts, Jasper Therapeutics (JSPR) has a Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Jasper Therapeutics (JSPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.